LevitasBio’s Post

🔬 Webinar Reminder! Revolutionize Your Single Cell Research with Scale Bio! 🧬 Are you tired of the limitations in single cell studies? Join our upcoming webinar to discover how Scale Bio is transforming the landscape of single cell experiments! Learn how to: •Scale projects to millions of cells without compromising quality •Multiplex 100s of samples per experiment with Scaleplex technology •Get 3x more cells within your current budget Perfect for researchers in: Single cell atlasing Drug discovery CRISPR genome-wide screens Large patient cohort studies Don't miss this opportunity to complete your large-scale projects in days, not months! Register now and unlock the power of affordable, high-throughput single cell analysis! https://hubs.la/Q02TkP5X0 #SingleCell #Genomics #Biotechnology #ResearchInnovation

🔬 Revolutionize Your Single Cell Research with Scale Bio! 🧬 Are you tired of the limitations in single cell studies? Join our upcoming webinar to discover how Scale Bio is transforming the landscape of single cell experiments! Learn how to: •Scale projects to millions of cells without compromising quality •Multiplex 100s of samples per experiment with Scaleplex technology •Get 3x more cells within your current budget Perfect for researchers in: Single cell atlasing Drug discovery CRISPR genome-wide screens Large patient cohort studies Don't miss this opportunity to complete your large-scale projects in days, not months! Register now and unlock the power of affordable, high-throughput single cell analysis! https://hubs.la/Q02RT0NV0 #SingleCell #Genomics #Biotechnology #ResearchInnovation

Read this nice blog from the Oncode Accelerator team on the network of the Federation of European Biochemical Societies (FEBS), with more detail on the Innovation Platforms and Workstreams within the program and our call for Demonstrator Projects. #FEBS #cancerresearch #drugdevelopment #oncodeaccelerator #biotech https://bit.ly/45F5eaJ

The demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them: https://lnkd.in/dwpgwtJP By Tony Hitchcock, principal and owner, AGH Bioconsulting

Last week we released our episode, How #RNA Origami is Revolutionizing Drug Development, featuring David Harrell, CEO of Helixomer, and Ryan M. Doxey, Senior Director of Technical Services at Kymanox. This episode has quickly become a favorite as it dives into the technical details behind RNA technology and how it can be utilized for structural purposes in drug development. David and Ryan explore how RNA origami creates precise, foldable structures, allowing for targeted drug delivery and intricate protein interactions—all without altering the genome. This innovative approach is reshaping possibilities for precision medicine and more adaptable therapies. Don’t miss out on the future of RNA in healthcare—catch up on the latest episode of The Factor! --------- 𝐖𝐚𝐧𝐭 𝐭𝐨 𝐬𝐭𝐚𝐲 𝐜𝐨𝐧𝐧𝐞𝐜𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐊𝐲𝐦𝐚𝐧𝐨𝐱: Follow Us: https://lnkd.in/e35y_dQq Get in Touch: www.kymanox.com Subscribe: https://lnkd.in/eYDXYarv

Dissociated tumor cells are a valuable tool in cancer researchers' arsenal. They offer significant advantages for in vitro drug screening and evaluation, personalized medicine applications, and modeling tumor heterogeneity. However, ethical considerations in sourcing starting materials and the limitations of DTCs must be carefully managed. Learn more: https://lnkd.in/ecqNf3Eq #Oncology #Biospecimens #CancerResearch #DrugDevelopment

Learn how the acquisition of Fluent BioSciences is paving the way for accessible and efficient single-cell sequencing. Our new article dives into the benefits of PIPseq V, from flexible workflows to cost savings. Plus, you can catch both Illumina and Fluent BioSciences at #ASHG24 for an in-depth talk on PIPseq V’s capabilities in scRNA-Seq!

Learn how the acquisition of Fluent BioSciences is paving the way for accessible and efficient single-cell sequencing. Our new article dives into the benefits of PIPseq V, from flexible workflows to cost savings. Plus, you can catch both Illumina and Fluent BioSciences at #ASHG24 for an in-depth talk on PIPseq V’s capabilities in scRNA-Seq!

Parse Biosciences, a leader in accessible and scalable single-cell sequencing solutions, welcomes OMAPiX as the newest member of its Certified Service Provider (CSP) Program. With this partnership, OMAPiX joins a distinguished network of service labs offering Parse’s scalable single cell technology to researchers worldwide. More: https://lnkd.in/g83ej575 #lifescience #biotech #healthcare

Mutation analysis is a valuable #diagnostics tool for many diseases, including cancer, and can support the development of diagnostic assays for specific #biomarkers for patient stratification. We support these efforts through standard mutation analysis for all solid tumors such as lung, colorectal, breast, and head and neck to name a few, as well as custom screening of tissues and biofluids with extraction, library preparation, #sequencing and #bioinformatics services available. If you’ve had difficulty finding the mutation cohort you need, we screen around 600 specimens with NGS data each month! Browse a tailored inventory of our specimens: https://lnkd.in/g5FvwDhA Or screen for #mutations: https://lnkd.in/gryUa3q4